Context Therapeutics Inc. - Common Stock (CNTX)

CUSIP: 21077P108

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class
Equity / Common Stock
Total 13F shares
74,175,436
Total 13F value
$194,338,022
Holder snapshot 6 visible 7 signals
Share change
+8,978,356
Put/Call ratio
203%
SEC-reported price per share
$2.62
Number of holders
59
Value change
+$28,627,264
Number of buys
32
Open additional details 1 more signal available
Number of sells
20
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
91,741,639

Security key

21077P108

Report period

Q1 2026

Institutions

59

Top holders

10

CNTX full security history Ownership snapshot Full 13F holder table Newer quarter: Q2 2026 Previous quarter: Q4 2025 Context Therapeutics Inc. SEC filings Context Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CNTX - Context Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
MPM BioImpact LLC
Disclosed value leader
Avidity Partners Manageme...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F 13D/G 3/4/5 Lead comparable stake: 12% 13D/G row: MPM BioImpact LLC Showing 1-6 of 15 holder rows.

Quick read

MPM BioImpact LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens MPM BioImpact LLC's linked filing trail.
Comparable ownership Top 5
MPM BioImpact LLC 12%
Avidity Partners Management LP 8.7%
Deep Track Capital, LP 8.3%
Soleus Capital Master Fund, L.P. 7.6%
Octagon Capital Advisors LP 5.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
MPM BioImpact LLC
13F 13D/G
Company
13F 13D/G
12%
from 13D/G
$15,698,705
10,679,391 shares
 — 31 Dec 2025
Avidity Partners Management LP
13D/G 13F
Company
13D/G 13F
8.7%
$21,753,357
8,302,808 shares
 -$2,352,163 31 Mar 2026
Deep Track Capital, LP
13F 13D/G
Company
13F 13D/G
8.3%
from 13D/G
$10,906,452
7,419,355 shares
 — 31 Dec 2025
Soleus Capital Master Fund, L.P.
13D/G
13D/G
7.6%
$18,243,429
6,963,141 shares
 +$5,729,267 31 Mar 2026
Octagon Capital Advisors LP
13D/G
13D/G
5.7%
$13,755,000
5,250,000 shares
 $0 31 Mar 2026
Blue Owl Capital Holdings LP
13D/G 13F
Company
13D/G 13F
5.5%
$13,333,219
5,089,015 shares
 -$3,324,552 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
59
Shares
74,175,436
Rows available
59
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
42
Q1 2026 holders
59
Holder diff
17
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .